Clinical Trial Update: A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating LUCEMYRA (lofexidine) for opioid withdrawal management in adolescent subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder
• Opioid Withdrawal

Drugs mentioned

• LUCEMYRA (LOFEXIDINE HYDROCHLORIDE)

Snippet

Sponsor: USWM, LLC (dba US WorldMeds) | Conditions: Opioid Withdrawal (Disorder), Opioid Use Disorder | Phase 1 | Status: WITHDRAWN